Drugs / LC51-0255
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04360343 | Jul → Oct 2020 | ulcerative colitis | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT03174613 | May 2017 → Jun 2019 | — | LG Chem | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04096573 | Apr 2020 → Nov 2021 | ulcerative colitis | LG Chem | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-12-21 | TransThera Sciences (Nanjing), Inc. | Regulatory 药捷安康宣布关键产品TT-01688（S1P1调节剂）治疗溃疡性结肠炎的中国II期临床试验IND申请获批 transthera.com ↗
双方合作开发的临床项目TT-01688（即 LC51-0255），一种治疗溃疡性结肠炎 （ulcerative colitis, “UC”）的全新的S1P1受体（鞘氨醇1－磷酸受体1）调节剂，获中国国家药品监督管理局(“NMPA”)批准开展II期临床试验。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-12-21 | TransThera Sciences (Nanjing), Inc. | 药捷安康宣布关键产品TT-01688（S1P1调节剂）治疗溃疡性结肠炎的中国II期临床试验IND申请获批 transthera.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LC51-0255 | “Drug: LC51-0255” NCT04360343 ↗ |
| Known as | SG82 | “LC51-0255 film-coated tablet (SG85) with LC51-0255 uncoated tablet (SG82)” NCT04360343 ↗ |
| Known as | SG85 | “LC51-0255 film-coated tablet (SG85) with LC51-0255 uncoated tablet (SG82)” NCT04360343 ↗ |
| Route | Oral | “tablets, PO” NCT03174613 ↗ |